Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TXP02
- Development stage
- Preclinical
- Lead developer
- Genovyn
- Modality
- Small Molecules
01
Overview
TXP02 is a preclinical-stage small molecule therapeutic candidate being developed by Genovyn under its Tripsovyn program for the treatment of triple-negative breast cancer (TNBC). It is designed to function as a non-apoptotic antioxidant ligase inhibitor, operating independently of traditional hormone or HER2 receptor pathways to target aggressive and hard-to-treat forms of breast cancer.
Beyond the preview
Go deeper on TXP02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TXP02.